Last reviewed · How we verify

Paliperidone and paliperidone palmitate — Competitive Intelligence Brief

Paliperidone and paliperidone palmitate (Paliperidone and paliperidone palmitate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry/Neurology.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Paliperidone and paliperidone palmitate (Paliperidone and paliperidone palmitate) — H. Lundbeck A/S. Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paliperidone and paliperidone palmitate TARGET Paliperidone and paliperidone palmitate H. Lundbeck A/S phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperdal,reminyl Risperdal,reminyl Jinan Mental Hospital marketed Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl) Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
Oral Olanzapine Oral Olanzapine Eli Lilly and Company marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
risperidone (Risperdal) risperidone (Risperdal) University of South Florida marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine or Risperidone + Aripiprazole Quetiapine or Risperidone + Aripiprazole Otsuka Pharmaceutical Development & Commercialization, Inc. marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor
Risperidone and Ramelteon Risperidone and Ramelteon All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + melatonin receptor agonist combination Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
SAPHRIS SAPHRIS Sun Pharmaceutical Industries Limited marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paliperidone and paliperidone palmitate — Competitive Intelligence Brief. https://druglandscape.com/ci/paliperidone-and-paliperidone-palmitate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: